Oncogenic IDH mutations increase heterochromatin-related replication stress without impacting homologous recombination-Reference-Cited by-同舟云学术

Oncogenic IDH mutations increase heterochromatin-related replication stress without impacting homologous recombination

Published:2023-07 Issue:13 Volume:83 Page:2347-2356.e8
ISSN:1097-2765
Container-title:Molecular Cell
language:en
Short-container-title:Molecular Cell

Author:

Schvartzman Juan-Manuel,Forsyth Grace,Walch Henry,Chatila Walid,Taglialatela Angelo,Lee Brian J.,Zhu Xiaolu,Gershik Steven,Cimino Francesco V.,Santella Anthony,Menghrajani Kamal,Ciccia Alberto,Koche Richard,Sánchez-Vega Francisco,Zha Shan,Thompson Craig B.^ORCID

Publisher

Elsevier BV

Subject

Cell Biology,Molecular Biology

Reference42 articles.

1. IDH mutation impairs histone demethylation and results in a block to cell differentiation;Lu;Nature,2012

2. Cancer-associated IDH1 mutations produce 2-hydroxyglutarate;Dang;Nature,2009

3. The Common feature of leukemia-associated IDH1 and IDH2 mutations is a neomorphic enzyme activity converting α-ketoglutarate to 2-hydroxyglutarate;Ward;Cancer Cell,2010

4. IDH1 and IDH2 mutations are frequent events in central chondrosarcoma and central and periosteal chondromas but not in other mesenchymal tumours;Amary;J. Pathol.,2011

5. 2-hydroxyglutarate inhibits MyoD-mediated differentiation by preventing H3K9 demethylation;Schvartzman;Proc. Natl. Acad. Sci. USA,2019

Cited by 10 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Treatment of IDH-mutant glioma in the INDIGO era;npj Precision Oncology;2024-07-19

2. BRCAness, DNA gaps, and gain and loss of PARP inhibitor–induced synthetic lethality;Journal of Clinical Investigation;2024-07-15

3. How to sensitize glioblastomas to temozolomide chemotherapy: a gap-centered view;Frontiers in Cell and Developmental Biology;2024-07-01

4. Molecular biology and novel therapeutics for IDH mutant gliomas: The new era of IDH inhibitors;Biochimica et Biophysica Acta (BBA) - Reviews on Cancer;2024-05

5. Therapeutic Targeting of DNA Repair Pathways in Pediatric Extracranial Solid Tumors: Current State and Implications for Immunotherapy;Cancers;2024-04-25